Trade Associations
Trade Associations
Here's a look at documents from national and international trade associations
Featured Stories
With family support, adults in rural China reduced blood pressure by average of 10 mm Hg
DALLAS, Texas, Nov. 9 [Category: Health Care] -- The American Heart Association posted the following news release:* * *
With family support, adults in rural China reduced blood pressure by average of 10 mm Hg
*
Research Highlights:
* Adults in rural villages in China who participated in the Healthy Family Program, a family-based intervention that involved regular blood pressure monitoring, the use of low-sodium salt substitutes and educational sessions on healthy lifestyle habits, achieved an average of 10 mm Hg reduction in systolic blood pressure compared to adults who did not participate ... Show Full Article DALLAS, Texas, Nov. 9 [Category: Health Care] -- The American Heart Association posted the following news release: * * * With family support, adults in rural China reduced blood pressure by average of 10 mm Hg * Research Highlights: * Adults in rural villages in China who participated in the Healthy Family Program, a family-based intervention that involved regular blood pressure monitoring, the use of low-sodium salt substitutes and educational sessions on healthy lifestyle habits, achieved an average of 10 mm Hg reduction in systolic blood pressure compared to adults who did not participatein the program.
* Six months after the program ended, the average systolic blood pressure for people who lived in participating villages remained 3.7 mm Hg lower compared to people who did not participate in the program, suggesting that they maintained the healthy habits they had developed during the programand that this family-based intervention could be effective in reducing blood pressure for people in rural or under-resourced communities.
* Note: The study featured in this news release is a research abstract. Abstracts presented at American Heart Association's scientific meetings are not peer-reviewed, and the findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.
Embargoed until 4:15 p.m. CT/5:15 p.m. ET, Sunday, Nov. 9, 2025
This news release contains updated information from the research authors that was not in the abstract.
NEW ORLEANS, Nov. 9, 2025 New research found family support helped adults in rural China reduce their blood pressure. Participants in a six-month, family-based program that included regular blood pressure monitoring, the use of low-sodium salt substitutes and educational classes on healthy lifestyle habits reduced their systolic blood pressure (the top number) by an average of 10 mm Hg compared to people who did not participate in the program, according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025. The meeting, Nov. 7-10, in New Orleans, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.
The Healthy Family Program was conducted in 80 villages throughout rural China, with approximately 30-50 families in each village. Half of the villages were randomly assigned to receive a family-focused intervention with multiple strategies to help lower blood pressure. Residents aged 40-80 years within participating families were eligible.
"Most blood pressure programs focus on treatment for people with high blood pressure, whereas our study included the whole family regardless of their blood pressure levels," said Professor Xin Du, M.D., Ph.D., co-principal investigator of the study, director of the Center of Heart Failure and Cardiomyopathy at Beijing Anzhen Hospital, Capital Medical University and director of the Ruyang Rural Health Institute.
In the participating villages, local health workers received training sessions to become family health instructors. As instructors, they trained one person from each household to become a "family leader" implementing the Healthy Family Program within the family.
Each participating family received a free blood pressure monitoring device and access to a smartphone app that provided automatic feedback on blood pressure readings and recommendations on when to seek medical care. Each family leader was responsible for regularly monitoring family members' blood pressure and entering the measurements into the app. People in participating villages also received free low-sodium, potassium-enriched salt substitutes to replace regular cooking salt and for use at the table with meals.
Family members without diagnosed high blood pressure also participated in the program. If their initial blood pressure measurement was normal (below 120/80 mm Hg), they were instructed to measure it again in three months. They were also encouraged to follow a diet prepared with the low-sodium salt, participate in group exercises and monitor their weight monthly.
The community health instructors and family leaders worked together to promote healthy lifestyles for all family members. The health instructors organized educational sessions for the family leaders on healthy lifestyle habits such as reducing salt intake, weight management, physical exercise and blood pressure control. After six months, the educational sessions and free salt substitutes were no longer provided in order to test whether the family members could independently maintain healthy lifestyle habits. The digital app, blood pressure monitoring devices and body weight scales remained available for participating families to continue using.
The study's key findings include:
* Adults who lived in participating villages achieved an average 10 mm Hg reduction in systolic blood pressure during the six months of the support program compared to people who lived in villages that did not participate.
* Six months after the program ended, the average systolic blood pressure for people who lived in participating villages remained 3.7 mm Hg lower compared to people who did not participate in the program, suggesting that they maintained some healthy habits they had developed during the program.
"In many cultures, families share the responsibility of caring for one another and promoting a healthy lifestyle. In our study, family leaders played a critical role in implementing the program by supporting a healthy diet high in vegetables, fruits and legumes, and low in sodium, fat and sugar. This is crucial for managing blood pressure, as well as for preventing other chronic health conditions, such as obesity and Type 2 diabetes," Du said.
Study details, background and design:
* The study included 8,001 adults, ages 40-80 years old, living in 80 villages throughout rural Mainland China.
* Half of the villages were assigned to receive the Healthy Family Program family-based intervention for six months, including a free home blood pressure monitor and low-sodium salt substitutes. Family leaders performed regular blood pressure monitoring and encouraged family members to participate in group exercises and educational sessions on healthy diet and weight management.
* Participants with initial blood pressure readings of 160/100 mm Hg or higher were required to measure their blood pressure the following day; those with readings of 140-159/90-99 mm Hg were instructed to measure within one week; and those with readings below 120/80 mm Hg were instructed to repeat measurement every three months.
* Adult family members with terminal illnesses (such as advanced cancer, advanced heart disease or end-stage kidney disease) or pregnancy plans were excluded from the study.
"This approach could transform how we prevent heart disease in communities worldwide. By involving entire families and communities rather than treating individuals, we can likely reduce everyone's risk of heart attack and stroke, especially in areas where health care resources are limited," Du said.
Study limitations:
* Researchers conducted the study in rural China, so more research is needed to determine if these results apply to other populations and health care systems.
* The intervention lasted only six months, which was not long enough to measure actual reductions in heart attack, stroke or death from heart disease.
* Some people who lived in the participating villages moved to cities for work during the study period and were not present for all of the intervention strategies, which may have affected the results.
* The program required support from the local government for recruitment and coordination, which may be necessary for successful implementation in other communities.
Co-authors, disclosures and funding sources are listed in the manuscript.
Statements and conclusions of studies that are presented at the American Heart Association's scientific meetings are solely those of the study authors and do not necessarily reflect the Association's policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association's scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.
The Association receives more than 85% of its revenue from sources other than corporations. These sources include contributions from individuals, foundations and estates, as well as investment earnings and revenue from the sale of our educational materials. Corporations (including pharmaceutical, device manufacturers and other companies) also make donations to the Association. The Association has strict policies to prevent any donations from influencing its science content and policy positions. Overall financial information is available here.
Additional Resources:
* Multimedia is available on the right column of the release link.
* View the abstract in the American Heart Association Scientific Sessions 2025 Online Program Planner
* American Heart Association news release: Target: BP initiative helps more than 10M adults with hypertension (Sept. 2025)
* American Heart Association Scientific Statement news release: New high blood pressure guideline emphasizes prevention, early treatment to reduce CVD risk (Aug. 2025)
* American Heart Association news release: Heart disease remains leading cause of death as key health risk factors continue to rise (Jan. 2025)
* American Heart Association health information: High Blood Pressure
* About Scientific Sessions 2025
* For more news at AHA Scientific Sessions 2025, follow us on X @HeartNews, #AHA25
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public's health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.
For Media Inquiries and American Heart Association Expert Perspective:
American Heart Association Communications & Media Relations in Dallas: 214-706-1173 ; ahacommunications@heart.org
Amanda Ebert: Amanda.Ebert@heart.org
For Public Inquiries: 1-800-AHA-USA1 (242-8721)
heart.org and stroke.org
***
Original text here: https://newsroom.heart.org/news/with-family-support-adults-in-rural-china-reduced-blood-pressure-by-average-of-10-mm-hg
UN Climate Talks Kick Off in Belem with Urgent Need for Greater Ambition from World Leaders
CAMBRIDGE, Massachusetts, Nov. 9 [Category: Environment] (TNSrpt) -- The Union of Concerned Scientists posted the following news release:* * *
UN Climate Talks Kick Off in Belem with Urgent Need for Greater Ambition from World Leaders
*
The U.N. annual climate change talks commence tomorrow in Belem, Brazil, where world leaders will be judged by whether they can agree to implement robust climate action that heeds the latest science and advances crucial issues of climate justice.
Nations' emission reduction commitments, or Nationally Determined Contributions (NDCs), have collectively fallen ... Show Full Article CAMBRIDGE, Massachusetts, Nov. 9 [Category: Environment] (TNSrpt) -- The Union of Concerned Scientists posted the following news release: * * * UN Climate Talks Kick Off in Belem with Urgent Need for Greater Ambition from World Leaders * The U.N. annual climate change talks commence tomorrow in Belem, Brazil, where world leaders will be judged by whether they can agree to implement robust climate action that heeds the latest science and advances crucial issues of climate justice. Nations' emission reduction commitments, or Nationally Determined Contributions (NDCs), have collectively fallenshort of the Paris Agreement goals, according to the U.N.'s latest NDC Synthesis Report. As such, Palau on behalf of the Association of Small Island States has proposed an agenda item to accelerate near-term climate ambition especially as the danger of surpassing the crucial 1.5 degrees Celsius goal is evident. Countries will also need to reach agreement on indicators for the Global Goal on Adaptation, an issue made more urgent by dire climate impacts already unfolding and most acutely harming the lowest income nations. Scaling up climate finance to at least $1.3 trillion by 2035 is the focus of the Baku to Belem Roadmap to support lower-income countries transition to clean energy and adapt to climate change.
The Trump administration is unlikely to send an official delegation to COP30, which would be a COP first, while the United States's formal exit from the Paris Agreement will take effect in January 2026. A contingent of U.S. leaders representing states, cities, Tribal nations, businesses and other institutions will be in Belem to demonstrate continued commitment to the goals of the Agreement.
Below is a statement by Dr. Rachel Cleetus, senior policy director for the Climate and Energy Program at the Union of Concerned Scientists (UCS). She has more than 20 years of experience working on international climate and energy issues, is a regular attendee of the annual U.N. climate talks and is attending COP30.
"World leaders coming to Belem must face up to the undeniable scientific and real-world evidence of their grossly insufficient efforts thus far to meet the goals of the Paris climate agreement. At COP30, they must commit to meeting their responsibilities to sharply cut heat-trapping emissions, ensure widespread access to affordable renewable energy, invest in a just phase out of fossil fuels and protect people from the ravages of climate change-fueled disasters. Breaching 1.5 C also has enormous consequences for climate Loss and Damage, as poorer nations on the frontlines of the climate crisis endure a steep toll resulting primarily from richer nations' failure to adequately curtail their heat-trapping emissions.
"It's in every nation's self-interest to limit dangerous climate change and embrace the economic and public health benefits of a clean energy transitionand it's in the global collective interest. The rest of the world must isolate the Trump administration in its deeply harmful actions and anti-science rhetoric and forge ahead to secure an ambitious global consensus. The time for further delay, zero sum thinking and hiding behind other countries' inaction is over as the planet teeters on the brink of overshooting 1.5 C of warming."
Below is a statement by Kate Cell, senior climate campaign manager at UCS and Climate Action Against Disinformation steering committee member and policy working group co-chair.
"This COP's proposed action agenda is the first to include information integrity as a key objective, creating a critical moment to demand that online search engines and platforms be held to the basic requirements of transparency, safety and accountability that regulate other products. The actions of some of the world's richest peopleleaders from the Big Tech sectorare contributing to climate denial, deception and delay just as leaders of the fossil fuel industry do. In much of the world, billions of daily online queries and interactions are an opportunity for Big Oil to serve dis-informing content with Big Tech's connivance. As the world faces increasing climate risk, most acutely experienced by the people least responsible for breaching 1.5 C, Big Tech billionaires have proved they are not to be trusted with a livable future for the generations to come. It is past time for systemic solutions to the problem of our polluted information ecosystem."
Below is a statement by Dr. Astrid Caldas, senior climate scientist for community resilience at UCS.
"The biodiversity impacts of climate change have been multiplying at an alarming rate as wildfires, drought, extreme heat and ocean acidification take a toll on the health of forests, oceans and species globally. Meanwhile, deforestation and changes in land use for agriculture and oil extraction have consequences not only for the environment but for Indigenous and traditional communities that have historically lived off and stewarded the land. Loss of species and other natural resources of cultural significance are undermining these communities' ability to live in their traditional ways. Action to prevent further warming is essential to the protection of biodiversity and ecosystems, which in turn helps prevent more future warming. At COP, nations must also commit to well-funded actions to protect forest ecosystems that recognize the rights of Indigenous peoples and directly include their participation in decision-making."
Additional UCS Resources:
* Media advisory listing UCS' COP30 experts available for interviews
* All blog posts related to COP30
* Statement on the U.N. Emissions Gap Report, confirming overshoot of 1.5 degrees Celsius
* Statement on President Trump's second withdrawal from the Paris Agreement
* * *
REPORT: https://unfccc.int/sites/default/files/resource/cma2025_08.pdf
***
Original text here: https://www.ucsusa.org/about/news/cop30-highlights-urgent-need-greater-ambition
U.S. Chamber Calls for Passage of Senate Package to Reopen Government
WASHINGTON, Nov. 9 [Category: Business] -- The U.S. Chamber of Commerce posted the following news release:* * *
U.S. Chamber Calls for Passage of Senate Package to Reopen Government
*
WASHINGTON, D.C. \- Today, the U.S. Chamber of Commerce released the below statement signaling support for the legislative package introduced today that would reopen and fund the government.
"The U.S. Chamber continues to call for an immediate end to the current government shutdown and applauds the Senators who have worked across the aisle to identify a path forward to reopening.
"Each day that the government ... Show Full Article WASHINGTON, Nov. 9 [Category: Business] -- The U.S. Chamber of Commerce posted the following news release: * * * U.S. Chamber Calls for Passage of Senate Package to Reopen Government * WASHINGTON, D.C. \- Today, the U.S. Chamber of Commerce released the below statement signaling support for the legislative package introduced today that would reopen and fund the government. "The U.S. Chamber continues to call for an immediate end to the current government shutdown and applauds the Senators who have worked across the aisle to identify a path forward to reopening. "Each day that the governmentremains closed is another day that our nation's economic and national security are at risk. We call for swift passage of the package released today to reopen and fund the government."
Last week, Chamber President and CEO Suzanne P. Clark called on Senate Democrats to immediately vote to reopen the federal government.
Since the onset of the shutdown, the Chamber has highlighted the harm it has inflicted on small businesses, the economy, and national security.
***
Original text here: https://www.uschamber.com/improving-government/u-s-chamber-calls-for-passage-of-senate-package-to-reopen-government
Heart attack risk halved in adults with heart disease taking tailored vitamin D doses
DALLAS, Texas, Nov. 9 [Category: Health Care] -- The American Heart Association posted the following news release:* * *
Heart attack risk halved in adults with heart disease taking tailored vitamin D doses
*
Research Highlights:
* Adults with heart disease prescribed vitamin D in doses tailored to reach blood levels considered optimal for heart health (>40-80 ng/mL) had a reduced risk of heart attack by more than half (52%) compared to those who did not receive monitoring of vitamin D levels.
* 85% of all study participants had vitamin D levels below 40 ng/mL at enrollment, and nearly ... Show Full Article DALLAS, Texas, Nov. 9 [Category: Health Care] -- The American Heart Association posted the following news release: * * * Heart attack risk halved in adults with heart disease taking tailored vitamin D doses * Research Highlights: * Adults with heart disease prescribed vitamin D in doses tailored to reach blood levels considered optimal for heart health (>40-80 ng/mL) had a reduced risk of heart attack by more than half (52%) compared to those who did not receive monitoring of vitamin D levels. * 85% of all study participants had vitamin D levels below 40 ng/mL at enrollment, and nearly52% of people in the treatment group needed to take more than 5,000 IU of vitamin D each day (more than six times the 800 IU daily value established by the FDA) to reach target blood levels of 40-80 ng/mL.
* Note: The study featured in this news release is a research abstract. Abstracts presented at American Heart Association's scientific meetings are not peer-reviewed, and the findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.
Embargoed until 9:15 a.m. CT/10:15 a.m. ET, Sunday, Nov. 9, 2025
This news release contains updated information from the research authors that was not in the abstract.
NEW ORLEANS, Nov. 9, 2025 Adults with heart disease who had a previous heart attack and took vitamin D doses tailored to reach optimal blood levels reduced their risk of another heart attack by more than half compared to those who did not have their vitamin D blood levels optimized, according to a preliminary study to be presented at the American Heart Association's Scientific Sessions 2025. The meeting, Nov. 7-10, in New Orleans, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.
Previous studies found low vitamin D levels are linked to worse heart health. The TARGET-D randomized clinical trial included adults with heart disease who also had a previous heart attack to determine whether achieving optimal vitamin D blood levels could prevent future heart attacks, strokes, heart failure hospitalizations or deaths. More than 85% of participants began the study with vitamin D levels in their blood below 40 ng/mL, a level many experts believe is insufficient for optimal health. Unlike earlier vitamin D randomized trials that used standard doses, the TARGET-D trial personalized the doses based on the results of each participant's blood test.
"Previous clinical trial research on vitamin D tested the potential impact of the same vitamin D dose for all participants without checking their blood levels first," said Heidi T. May, Ph.D., M.S.P.H., FAHA, principal investigator of TARGET-D and an epidemiologist and professor of research at Intermountain Health in Salt Lake City, Utah. "We took a different approach. We checked each participant's vitamin D levels at enrollment and throughout the study, and we adjusted their dose as needed to bring and maintain them in a range of 40-80 ng/mL."
Participants in the TARGET-D study were randomized to two groups: The standard of care group did not receive management of their vitamin D levels, and the treatment group received tailored vitamin D supplementation, with doses adjusted every three months until their vitamin D blood levels were above 40 ng/mL. Once the vitamin D level was above 40 ng/mL, levels were checked annually and doses adjusted if levels dropped below that target.
Researchers monitored both vitamin D and calcium levels for the participants in the treatment group throughout the study to prevent vitamin D toxicity. Doses were reduced or stopped if vitamin D levels rose above 80 ng/mL. Excessive vitamin D can lead to hypercalcemia (higher-than-normal levels of calcium in the blood), kidney failure and abnormal heart rhythm.
The study's key findings include:
* People who received personalized dosing of vitamin D supplements to achieve vitamin D levels greater than 40 ng/mL for nearly four years had a 52% lower risk of heart attack compared to participants whose vitamin D levels were not managed.
* More than 85% of participants had vitamin D levels below 40 ng/mL when they enrolled in the study.
* Nearly 52% of participants in the treatment group required more than 5,000 IU of vitamin D each day to reach the target blood levels of greater than 40 ng/mL. This dose is more than six times the FDA-recommended daily intake of 800 IU.
The study primarily focused on whether or not optimal levels of vitamin D could help reduce the risk of serious events like heart attack, heart failure, stroke or death among adults with heart disease. Researchers found that tailored vitamin D doses did not significantly reduce the primary outcome of death, heart failure hospitalization or stroke; however, supplementation appeared to be beneficial for preventing heart attack specifically.
May says that these results could improve patient care by focusing on blood tests for vitamin D levels and tailoring doses. "We encourage people with heart disease to discuss vitamin D blood testing and targeted dosing with their health care professionals to meet their individual needs," she added.
May and her study colleagues emphasized that more clinical trials are needed to determine whether targeted treatment with vitamin D could help prevent heart disease, before a first cardiac event.
Before adding or changing a vitamin regimen, the American Heart Association encourages people with heart disease to consult their cardiologist.
The study had several limitations. Only adults with a diagnosis of heart disease were included, so the results may not apply to people without heart disease. In addition, the smaller number of participants means a more complete analysis of other conditions and outcomes was not possible. In addition, most participants were from the same racial group, with approximately 90% self-identifying as white, so additional research is needed to determine whether the results apply to people of all backgrounds.
Study details, background and design:
* The study enrolled 630 adults with acute coronary syndrome treated at Intermountain Medical Center in Utah from April 2017 to May 2023, with an average follow-up of 4.2 years.
* Participants were an average age of 63 years old, 78% were men, and 48% had a previous heart attack.
* Participants were randomly assigned to one of two groups: The treatment group received targeted vitamin D supplementation to achieve optimal levels, with ongoing dose adjustments every three months based on blood testing to reach and maintain vitamin D levels above 40 ng/mL but not over 80 ng/mL. There was no vitamin D monitoring or dose-tailoring for patients in the standard care group.
* About 52% of study participants in the treatment group with vitamin D levels below 40 ng/mL began taking 5,000 IU daily as their starting dose.
* A total of 107 major cardiac events, including heart attack, heart failure hospitalization, stroke or death, occurred during the study period (15.7% occurred in the treatment group, and 18.4% occurred in the standard care group).
Co-authors, disclosures and funding sources are listed in the abstract.
Statements and conclusions of studies that are presented at the American Heart Association's scientific meetings are solely those of the study authors and do not necessarily reflect the Association's policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association's scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.
The Association receives more than 85% of its revenue from sources other than corporations. These sources include contributions from individuals, foundations and estates, as well as investment earnings and revenue from the sale of our educational materials. Corporations (including pharmaceutical, device manufacturers and other companies) also make donations to the Association. The Association has strict policies to prevent any donations from influencing its science content and policy positions. Overall financial information is available here.
Additional Resources:
* Multimedia is available on the right column of the release link
* Spanish news release
* View the abstract in the American Heart Association's Scientific Sessions 2025 Online Program Planner
* American Heart Association news release: Some benefits, potential risks with alternative medicines for heart failure (Dec. 2022)
* American Heart Association health information: Dietary Supplements: Hype or Help for Good Health
* American Heart Association health information: Life After a Heart Attack
* About Scientific Sessions 2025
* For more news at the American Heart Association's Scientific Sessions 2025, follow us on X @HeartNews,#AHA25
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public's health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.
For Media Inquiries and American Heart Association Expert Perspective: 214-706-1173
American Heart Association Communications & Media Relations in Dallas: ahacommunications@heart.org
Amanda Ebert: Amanda.Ebert@heart.org
For Public Inquiries: 1-800-AHA-USA1 (242-8721)
heart.org and stroke.org
***
Original text here: https://newsroom.heart.org/news/heart-attack-risk-halved-in-adults-with-heart-disease-taking-tailored-vitamin-d-doses
Diabetes drug reduced irregular heartbeat events in overweight/obese adults with AFib
DALLAS, Texas, Nov. 9 [Category: Health Care] -- The American Heart Association posted the following news release:* * *
Diabetes drug reduced irregular heartbeat events in overweight/obese adults with AFib
*
Research Highlights:
* Adults with atrial fibrillation and obesity/overweight (but no diabetes) who took the diabetes medication metformin after a rhythm correction procedure were more likely to stay free of AFib episodes for a year.
* Weight loss was not thought to be the main reason metformin helped, since there was only a modest weight change among those taking the medication. ... Show Full Article DALLAS, Texas, Nov. 9 [Category: Health Care] -- The American Heart Association posted the following news release: * * * Diabetes drug reduced irregular heartbeat events in overweight/obese adults with AFib * Research Highlights: * Adults with atrial fibrillation and obesity/overweight (but no diabetes) who took the diabetes medication metformin after a rhythm correction procedure were more likely to stay free of AFib episodes for a year. * Weight loss was not thought to be the main reason metformin helped, since there was only a modest weight change among those taking the medication.
* Future studies may compare the impact of metformin with other diabetes medications in treating adults with obesity and AFib.
* Note: The study featured in this news release is a research abstract. Abstracts presented at American Heart Association's scientific meetings are not peer-reviewed, and the findings are considered preliminary until published as full manuscripts in a peer-reviewed scientific journal.
Embargoed until 8:30 a.m. CT/9:30 a.m. ET, Sunday, Nov. 9, 2025
This news release contains updated information from the research authors that was not in the abstract.
NEW ORLEANS, Nov. 9, 2025 People with atrial fibrillation (AFib) and obesity may have fewer episodes of AFib after ablation if they take the diabetes medication metformin in addition to standard care, according to a preliminary, late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025. The meeting, Nov. 7-10, in New Orleans, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.
"Lifestyle and risk factor modification efforts are essential to treating AFib and according to the results of our study could be aided by taking metformin," said Amish Deshmukh, M.D., lead author of the study and clinical assistant professor of medicine at the University of Michigan in Ann Arbor.
According to the American Heart Association, AFib, marked by episodes of irregular and rapid heartbeat, is the most common heart rhythm disorder and can lead to blood clots, stroke, heart failure or other heart-related conditions.
Metformin is a widely prescribed generic medication that helps control blood sugar levels, primarily in people with Type 2 diabetes. It is often used as an initial treatment due to its effectiveness, long history of use and relatively low cost.
In previous research on adults with diabetes and obesity, those taking metformin to manage blood sugar and weight had a lower risk of AFib as compared to other antidiabetic agents. In studies of laboratory models (for example, cells or animals), metformin directly affected heart cells and reduced irregular heart rhythms. Researchers wanted to find out if metformin can help lower the chances of AFib returning in people treated for AFib who are overweight or obese.
The Metformin as an Adjunctive Therapy to Catheter Ablation of Atrial Fibrillation (META-AF) study analyzed 99 adults with AFib and obesity or overweight to determine whether adding metformin to standard care after a catheter ablation procedure would be beneficial. All participants received ablation and then were randomly selected to receive either usual care (lifestyle education about physical activity, healthy eating, sleep and managing other medical conditions) or usual care plus metformin.
During the year after ablation, the analysis found:
* 78% of the metformin group versus 58% of the usual-care group had no episodes of AFib lasting 30 seconds or more.
* The metformin group had fewer patients who needed a repeat ablation or electric shock to restore a normal heart rhythm during an AFib episode (6% versus 16%, respectively).
* The metformin group had less frequent AFib episodes during heart rhythm monitoring compared to the usual care group (8% versus 16%, respectively).
* Antiarrhythmia medications were used after ablation in 8% of patients in the metformin group and 18% in usual care.
* Weight changes were minimal in all participants, consistent with prior studies of metformin use in people without diabetes.
"Treatment with metformin in people with obesity who do not have diabetes and are undergoing AFib ablation seems to lower the likelihood of recurrent AFib or atrial arrhythmias after a single procedure. While most people tolerated the medication well, a significant number stopped taking it due to side effects or because they felt well and did not want to add another medication to their regimen," Deshmukh said.
The results raise the question of whether other medications for diabetes and weight loss, such as GLP-1 receptor agonists, may have similar benefits and side effects in adults without diabetes with AFib and obesity.
Obesity is a common risk factor for AFib, and recurrent episodes of irregular heartbeats are more common in obese and overweight patients after catheter ablation, a procedure to eliminate small areas of tissue generating abnormal heartbeats. According to the American Heart Association's 2025 Heart Disease and Stroke Statistics, AFib currently affects more than 6 million people in the U.S.
"I would suggest conducting a larger study to investigate metformin and other diabetes treatments. We know that many of these medications offer cardiovascular benefits, and we are starting to gain a better understanding of how they might specifically benefit patients with arrhythmias. A study comparing various medications would be valuable to confirm our findings and also to address questions about tolerability, the feasibility of long-term use and costs," Deshmukh said.
The study is limited by being small and conducted at one medical center. In addition, the findings may not be generalizable to centers with different populations or different techniques for performing catheter ablation.
Study details, background or design:
* The study included 99 adults (average age of 63 years; 70% men, mostly white adults) with AFib. 70% of participants were categorized as obese, and the rest were categorized as overweight. 22% of participants had undergone a previous ablation. 46% had AFib that stopped without treatment within a week.
* Participants were excluded from the study if they had Type 1 or Type 2 diabetes, although 40% had blood sugar levels that met the criteria for prediabetes (A1C results of between 5.7%-6.4%).
* Additionally, people who were taking other medications to treat diabetes or those for whom metformin would be harmful were also excluded from this study.
* All participants were taking blood thinners to help lower the risk of stroke.
* The ablation procedure was performed in the pulmonary veins, which is known to be a common possible trigger area for AFib.
* No placebo was used, and the participants knew which treatment group they were in (49 were randomized to metformin and 50 to usual care).
* After a 3-month period to allow for healing after ablation and increasing metformin to the maximum dose, patients were monitored for recurrence of AFib lasting at least 30 seconds.
* Researchers calculated the AFib burden (percent of monitored time spent in AFib based on information from clinical monitoring, handheld monitors, pacemakers and defibrillators) over the one year (at 3-months and at 12-months).
* A significant number of study participants (12 of 49) stopped taking metformin due to side effects or because they felt better or didn't want to add a medication to their regimen.
* The study was conducted at the University of Michigan between 2021 and 2025.
Co-authors, disclosures and funding sources are listed in the abstract.
Statements and conclusions of studies that are presented at the American Heart Association's scientific meetings are solely those of the study authors and do not necessarily reflect the Association's policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association's scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.
The Association receives more than 85% of its revenue from sources other than corporations. These sources include contributions from individuals, foundations and estates, as well as investment earnings and revenue from the sale of our educational materials. Corporations (including pharmaceutical, device manufacturers and other companies) also make donations to the Association. The Association has strict policies to prevent any donations from influencing its science content and policy positions. Overall financial information is available here.
Additional Resources:
* Multimedia is available on the right column of the release link.
* View the abstract in the American Heart Association Scientific Sessions 2025 Online Program Planner
* American Heart Association news release: Lifestyle & risk factor changes improved AFib symptoms, not burden, over standard care (Nov. 2024)
* American Heart Association news release: Lifestyle changes, meds effective to prevent or delay Type 2 diabetes; no change in CVD (May 2022)
* 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
* For more news at the American Heart Association's Scientific Sessions 2025, follow us on X @HeartNews,#AHA25
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public's health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.
For Media Inquiries and American Heart Association Expert Perspective:
American Heart Association Communications & Media Relations in Dallas: 214-706-1173 ; ahacommunications@heart.org
Karen Astle: Karen.Astle@heart.org
For Public Inquiries: 1-800-AHA-USA1 (242-8721)
heart.org and stroke.org
***
Original text here: https://newsroom.heart.org/news/diabetes-drug-reduced-irregular-heartbeat-events-in-overweightobese-adults-with-afib
Cup of coffee a day may not be harmful for some adults with AFib and could lower episodes
DALLAS, Texas, Nov. 9 [Category: Health Care] -- The American Heart Association posted the following news release:* * *
Cup of coffee a day may not be harmful for some adults with AFib and could lower episodes
*
Research Highlights:
* During the 6 months after treatment to restore a normal heart rhythm, adults with atrial fibrillation (AFib) who were randomly assigned to drink coffee every day were 39% less likely to have a recurrence of AFib compared to participants assigned to not have any coffee or other caffeinated drinks.
* The results of the 200-person trial may challenge the common ... Show Full Article DALLAS, Texas, Nov. 9 [Category: Health Care] -- The American Heart Association posted the following news release: * * * Cup of coffee a day may not be harmful for some adults with AFib and could lower episodes * Research Highlights: * During the 6 months after treatment to restore a normal heart rhythm, adults with atrial fibrillation (AFib) who were randomly assigned to drink coffee every day were 39% less likely to have a recurrence of AFib compared to participants assigned to not have any coffee or other caffeinated drinks. * The results of the 200-person trial may challenge the commonbelief that caffeine may spur more abnormal heart rhythms such as AFib.
* Researchers say it is reasonable for health care professionals to let their AFib patients try naturally caffeinated drinks like tea and coffee if they enjoy them. However, some people may still find that caffeine, including caffeinated coffee, may trigger or worsen their AFib symptoms.
* Note: This trial is simultaneously published today as a full manuscript in the peer-reviewed scientific journal JAMA.
Embargoed until 8:45 a.m. CT/9:45 a.m. ET, Sunday, Nov. 9, 2025
NEW ORLEANS, Nov. 9, 2025 Adults treated for atrial fibrillation (AFib) who drank a daily cup of coffee were 39% less likely to have an irregular heart rhythm episode compared to those who avoided all caffeinated products, according to a new study. The preliminary late-breaking science was presented today at the American Heart Association's Scientific Sessions 2025. The meeting, Nov. 7-10, in New Orleans, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.
"We conducted this study to assess whether caffeinated coffee increased or decreased the risk of AFib. Participants were randomly assigned to continue drinking at least one cup of caffeinated coffee daily or to avoid any caffeine for 6 months," said study lead author Christopher X. Wong, M.B.B.S., M.Sc., M.P.H., Ph.D., formerly of the University of California, San Francisco, and currently professor of cardiology at the University of Adelaide in Australia.
The Does Eliminating Coffee Avoid Fibrillation (DECAF) trial enrolled 200 adults diagnosed with AFib who experienced an irregular, fast heart rhythm and were about to be treated with cardioversion therapy, using medication or an electrical shock to restore a normal rhythm. Participants reported that they typically drank about one cup of caffeinated coffee per day, and they agreed to follow the researchers' advice on caffeine for 6 months after the cardioversion therapy. Half of the participants were randomly chosen to continue drinking at least one cup of coffee daily, and the other half were instructed to avoid all caffeine.
During the 6-month study:
* The coffee group maintained their pre-enrollment habit of drinking about 1 cup of coffee a day, while the no coffee group reported that they consumed no caffeine each day.
* 47% of the participants in the coffee group had a recurrent AFib or atrial flutter (rapid but regular heartbeat) episode lasting more than 30 seconds, compared with 64% of the no-caffeine group, representing a 39% lower risk among the coffee drinkers.
* Similar reductions in risk were found when only AFib episodes (excluding atrial flutter episodes) were considered.
"Our study results suggest that caffeinated coffee may not be responsible for raising the risk of AFib and may even reduce it," said senior study author Gregory M. Marcus, M.D., M.A.S., a professor of medicine at the University of California, San Francisco.
This study enrolled only people who already drink coffee, so future studies might investigate whether AFib episodes are reduced in people who start drinking coffee or other caffeinated beverages for the first time.
Because the study participants consumed about one cup of coffee per day, the results may not apply to people who drink more coffee or other beverages containing caffeine, such as energy drinks.
"It is reasonable for health care professionals to let their AFib patients consider experimenting with naturally caffeinated substances that they may enjoy, such as caffeinated tea and coffee. However, some people may still find that caffeine or caffeinated coffee triggers or worsens their AFib," Marcus said.
AFib currently affects more than 6 million people in the U.S. and can lead to blood clots, stroke, heart failure and other heart-related conditions, according to the American Heart Association's 2025 Heart Disease and Stroke Statistics.
Study details, background and design:
* The study enrolled 200 adults (average age of 69 years; 71% men; 80% self-identified as white adults) with AFib who usually drank about 1 cup of coffee per day.
* After the heart rhythm was successfully returned to normal using either medication or electric shock, participants were eligible to enroll and were randomly assigned to either continue drinking at least one cup of coffee daily or to avoid all caffeine for the next 6 months.
* Half of the participants were already taking medications to prevent irregular heart rhythm episodes, and they continued to take the prescribed medications throughout the trial.
* All participants were followed for up to 6 months for the recurrence of AFib or atrial flutter that lasted more than 30 seconds. The episodes were verified by their health care professional or on personal health devices with a medical-grade electrocardiogram. The episodes were then entered in the participants' medical records.
* The study was conducted at five health care centers in the United States, Australia and Canada, with participants enrolled between 2021 and 2024.
* Drinking coffee and other caffeinated beverages was self-reported by participants in three detailed phone interviews during the study.
Co-authors, disclosures and funding sources are listed in the abstract.
Statements and conclusions of studies that are presented at the American Heart Association's scientific meetings are solely those of the study authors and do not necessarily reflect the Association's policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association's scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.
The Association receives more than 85% of its revenue from sources other than corporations. These sources include contributions from individuals, foundations and estates, as well as investment earnings and revenue from the sale of our educational materials. Corporations (including pharmaceutical, device manufacturers and other companies) also make donations to the Association. The Association has strict policies to prevent any donations from influencing its science content and policy positions. Overall financial information is available here.
Additional Resources:
* Multimedia is available on the right column of the release link.
* View the abstract in the American Heart Association Scientific Sessions 2025 Online Program Planner
* American Heart Association news release: Drinking coffee may help prevent mental decline in people with atrial fibrillation (Dec. 2024)
* American Heart Association news release: Drinking 2 or more cups of coffee daily may double risk of heart death in people with severe hypertension (Dec. 2022)
* American Heart Association health information: Caffeine and Heart Disease
* About Scientific Sessions 2025
* For more news at the American Heart Association's Scientific Sessions 2025, follow us on X @HeartNews,#AHA25
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public's health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.
For Media Inquiries and American Heart Association Expert Perspective:
American Heart Association Communications & Media Relations in Dallas: 214-706-1173 ; ahacommunications@heart.org
Karen Astle: Karen.Astle@heart.org
For Public Inquiries: 1-800-AHA-USA1 (242-8721)
heart.org and stroke.org
***
Original text here: https://newsroom.heart.org/news/cup-of-coffee-a-day-may-not-be-harmful-for-some-adults-with-afib-and-could-lower-episodes
Chance to win cash doubled medication use, yet led to similar blood pressure reductions
DALLAS, Texas, Nov. 9 [Category: Health Care] -- The American Heart Association posted the following news release:* * *
Chance to win cash doubled medication use, yet led to similar blood pressure reductions
*
Research Highlights:
* A study of 400 adults with high blood pressure found that participants were twice as likely to take their blood pressure medication (measured by electronic pill bottles that recorded when bottles were opened) when they could win a daily cash reward compared to people who were not offered a potential reward.
* Despite taking their blood pressure medication ... Show Full Article DALLAS, Texas, Nov. 9 [Category: Health Care] -- The American Heart Association posted the following news release: * * * Chance to win cash doubled medication use, yet led to similar blood pressure reductions * Research Highlights: * A study of 400 adults with high blood pressure found that participants were twice as likely to take their blood pressure medication (measured by electronic pill bottles that recorded when bottles were opened) when they could win a daily cash reward compared to people who were not offered a potential reward. * Despite taking their blood pressure medicationmore consistently, participants who were eligible for cash rewards had similar blood pressure reductions compared to the people who were not offered rewards.
* When the rewards program ended after six months, participants in the rewards group returned to their previous habits of not taking medication as prescribed.
* Note: This trial is simultaneously published today as a full manuscript in the peer-reviewed scientific journal JACC.
Embargoed until 3:45 p.m. CT/4:45 p.m. ET, Sunday, Nov. 9, 2025
This news release contains updated information from the research authors that was not in the abstract.
NEW ORLEANS, Nov. 9, 2025 People with high blood pressure were twice as likely to take their blood pressure medication regularly when offered daily chances to win cash rewards, yet they did not achieve better blood pressure measurements compared to people who were not offered financial rewards, according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025. The meeting, Nov. 7-10, in New Orleans, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.
The Behavioral Economics Trial To Enhance Regulation of Blood Pressure (BETTER-BP) study included 400 adults with high blood pressure who received care at three community health clinics in New York City. These clinics provide health care mainly to people with Medicaid coverage (who are low-income or disabled) and people without health insurance. Both groups often have higher rates of uncontrolled blood pressure and are less likely to consistently take their blood pressure medication, according to prior studies. Not taking blood pressure medication as directed can increase the risk of heart attack and stroke, according to the American Heart Association.
The participants were randomly assigned to one of two groups: 1) two-thirds were eligible to win cash rewards for taking their blood pressure medication, and 2) one-third were in a control group that was not offered the chance to win cash for taking their blood pressure medication. All of the participants self-reported that they did not take their blood pressure medication as prescribed before the study began. Researchers used electronic pill bottles to monitor how often participants opened their medication bottles during the study period (as a measure of daily medication use), rather than relying on patients self-reporting this information. The average systolic blood pressure (the top number) among all participants was 139 mm Hg at the time of enrollment in the study. (Normal systolic blood pressure is less than 120 mm Hg, according to the American Heart Association's 2025 High Blood Pressure Guideline.)
"We're always looking for ways to improve medication adherence among our patients with heart disease, and high blood pressure is one of the most preventable risk factors for heart disease," said John Dodson, M.D., principal investigator of the study and associate professor of medicine and population health at the NYU Grossman School of Medicine in New York City.
Participants in the rewards group were entered into a daily drawing for a cash reward ranging from $5-$50 if they had opened their pill bottle the previous day (indicating that they had taken their blood pressure medication). They received daily text messages informing them if they had won any money. In addition, people who did not open their medication bottle (indicating they had skipped their previous day's dose) received a text message from the study app reminding them they could have potentially won a cash reward if they had taken their medication the previous day. People in the control group did not receive any text messages and were not eligible to win any cash rewards.
The study monitored participants for 12 months total: six months of the rewards program followed by six months of additional monitoring without rewards to look for changes in medication-taking habits after the financial incentives ended.
The study's key findings include:
* Financial incentives doubled consistent medication use, with 71% of participants in the rewards group opening their medication regularly (at least 80% of the time over the six-month study period), compared to 34% of people in the control group who were not given the opportunity to receive cash rewards.
* People in both groups experienced similar reductions in systolic blood pressure at six months. People in the rewards group had an average 6.7 mm Hg reduction compared to an average 5.8 mm Hg reduction in the control group.
* After the cash rewards ended, the study found that those participants reverted to their previous behavior of not consistently taking their medication as prescribed.
"Financial incentives clearly worked to change behavior during the study period because people in the rewards group took their medication much more consistently. However, we were surprised that the behavior change didn't translate to significantly better blood pressure control," Dodson said. "It is unclear if there was no change because they opened the bottles but didn't take the medication tracked, or if a different medication or lifestyle behavior not tracked in the study impacted their blood pressure."
"We were also surprised that people did not keep taking their medication as prescribed after the rewards program ended. This shows that improving medication adherence is more complex than we thought. There are still many unknown factors we need to understand in order to help people adopt long-term behavior changes," he added.
The study had several limitations. The electronic pill bottles only monitored whether the bottles were opened, not whether the participants actually took the medication. Researchers monitored only one blood pressure medication per participant, even though many participants were prescribed multiple medications for high blood pressure. The study also used standardized office blood pressure measurements taken at three points during the trial (at enrollment, after six months and at 12 months, six months after the end of the rewards program), rather than more frequent home monitoring, which may have yielded different results.
Study details, background and design:
* The study included 400 adults with a diagnosis of high blood pressure who were prescribed at least one blood pressure medication and had at least one systolic blood pressure measurement of over 140 mm Hg in the past year.
* There were 265 people in the rewards group and 135 in the control (no rewards) group.
* Participants were a median age of 57 years old; 60.5% were women; 61.5% of participants self-identified as Hispanic, 20.3% as Black, 3.3% as non-Hispanic white, 2.8% as Asian and 12.3% as other.
* In addition to having high blood pressure, 54.5% of participants had obesity (BMI >=30), and 46.5% had Type 2 diabetes.
* More than 70% of participants were covered by Medicaid (due to having low income or a disability) or they had no health insurance.
Co-authors, disclosures and funding sources are listed in the manuscript.
Statements and conclusions of studies that are presented at the American Heart Association's scientific meetings are solely those of the study authors and do not necessarily reflect the Association's policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association's scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.
The Association receives more than 85% of its revenue from sources other than corporations. These sources include contributions from individuals, foundations and estates, as well as investment earnings and revenue from the sale of our educational materials. Corporations (including pharmaceutical, device manufacturers and other companies) also make donations to the Association. The Association has strict policies to prevent any donations from influencing its science content and policy positions. Overall financial information is available here.
Additional Resources:
* Multimedia is available on the right column of the release link.
* View the abstract in the American Heart Association Scientific Sessions 2025 Online Program Planner
* American Heart Association news release: Target: BP initiative helps more than 10M adults with hypertension (Sept. 2025)
* American Heart Association Scientific Statement news release: The PREVENTTM equations can improve, personalize care for adults with high BP (Aug. 2025)
* American Heart Association Scientific Statement news release: New high blood pressure guideline emphasizes prevention, early treatment to reduce CVD risk (Aug. 2025)
* American Heart Association health information: High Blood Pressure
* American Heart Association health information: Managing High Blood Pressure Medications
* About Scientific Sessions 2025
* For more news at AHA Scientific Sessions 2025, follow us on X @HeartNews,#AHA25
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public's health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.
For Media Inquiries and American Heart Association Expert Perspective:
American Heart Association Communications & Media Relations in Dallas: 214-706-1173 ; ahacommunications@heart.org
Amanda Ebert: Amanda.Ebert@heart.org
For Public Inquiries: 1-800-AHA-USA1 (242-8721)
heart.org and stroke.org
***
Original text here: https://newsroom.heart.org/news/chance-to-win-cash-doubled-medication-use-yet-led-to-similar-blood-pressure-reductions